Channel Therapeutics Corporation (CHRO) Stock Competitors & Peer Comparison
See (CHRO) competitors and their performances in Stock Market.
Peer Comparison Table: Biotechnology Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| CHRO | $1.35 | +7.14% | 8.9M | -0.11 | -$12.00 | N/A |
| VRTX | $515.54 | -2.65% | 132.5B | 27.74 | $18.82 | N/A |
| VRNA | $106.91 | +0.11% | 72.7B | -102.80 | -$1.04 | N/A |
| REGN | $667.20 | +2.68% | 69.7B | 14.82 | $45.63 | +0.54% |
| ARGX | $917.25 | +0.05% | 56.9B | 83.03 | $11.08 | N/A |
| SGEN | $228.74 | -0.07% | 43.2B | -57.19 | -$4.00 | N/A |
| ALNY | $321.05 | +2.56% | 42.9B | 57.94 | $5.55 | N/A |
| RVMDW | $9.80 | +0.00% | 41B | -2.35 | -$4.15 | N/A |
| RVMD | $188.90 | -0.57% | 40.5B | -26.94 | -$7.07 | N/A |
| ONC | $303.03 | -2.08% | 33B | 69.12 | $4.47 | N/A |
Stock Comparison
CHRO vs VRTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, VRTX has a market cap of 132.5B. Regarding current trading prices, CHRO is priced at $1.35, while VRTX trades at $515.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas VRTX's P/E ratio is 27.74. In terms of profitability, CHRO's ROE is -1.64%, compared to VRTX's ROE of +0.24%. Regarding short-term risk, CHRO is more volatile compared to VRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check VRTX's competition here
CHRO vs VRNA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, VRNA has a market cap of 72.7B. Regarding current trading prices, CHRO is priced at $1.35, while VRNA trades at $106.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas VRNA's P/E ratio is -102.80. In terms of profitability, CHRO's ROE is -1.64%, compared to VRNA's ROE of -0.02%. Regarding short-term risk, CHRO is more volatile compared to VRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check VRNA's competition here
CHRO vs REGN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, REGN has a market cap of 69.7B. Regarding current trading prices, CHRO is priced at $1.35, while REGN trades at $667.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas REGN's P/E ratio is 14.82. In terms of profitability, CHRO's ROE is -1.64%, compared to REGN's ROE of +0.14%. Regarding short-term risk, CHRO is more volatile compared to REGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check REGN's competition here
CHRO vs ARGX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ARGX has a market cap of 56.9B. Regarding current trading prices, CHRO is priced at $1.35, while ARGX trades at $917.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ARGX's P/E ratio is 83.03. In terms of profitability, CHRO's ROE is -1.64%, compared to ARGX's ROE of +0.22%. Regarding short-term risk, CHRO is more volatile compared to ARGX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ARGX's competition here
CHRO vs SGEN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, SGEN has a market cap of 43.2B. Regarding current trading prices, CHRO is priced at $1.35, while SGEN trades at $228.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas SGEN's P/E ratio is -57.19. In terms of profitability, CHRO's ROE is -1.64%, compared to SGEN's ROE of -0.21%. Regarding short-term risk, CHRO is more volatile compared to SGEN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check SGEN's competition here
CHRO vs ALNY Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ALNY has a market cap of 42.9B. Regarding current trading prices, CHRO is priced at $1.35, while ALNY trades at $321.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ALNY's P/E ratio is 57.94. In terms of profitability, CHRO's ROE is -1.64%, compared to ALNY's ROE of +0.98%. Regarding short-term risk, CHRO is more volatile compared to ALNY. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ALNY's competition here
CHRO vs RVMDW Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RVMDW has a market cap of 41B. Regarding current trading prices, CHRO is priced at $1.35, while RVMDW trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RVMDW's P/E ratio is -2.35. In terms of profitability, CHRO's ROE is -1.64%, compared to RVMDW's ROE of -0.83%. Regarding short-term risk, CHRO is more volatile compared to RVMDW. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RVMDW's competition here
CHRO vs RVMD Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RVMD has a market cap of 40.5B. Regarding current trading prices, CHRO is priced at $1.35, while RVMD trades at $188.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RVMD's P/E ratio is -26.94. In terms of profitability, CHRO's ROE is -1.64%, compared to RVMD's ROE of -0.83%. Regarding short-term risk, CHRO is more volatile compared to RVMD. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RVMD's competition here
CHRO vs ONC Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ONC has a market cap of 33B. Regarding current trading prices, CHRO is priced at $1.35, while ONC trades at $303.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ONC's P/E ratio is 69.12. In terms of profitability, CHRO's ROE is -1.64%, compared to ONC's ROE of +0.12%. Regarding short-term risk, CHRO is more volatile compared to ONC. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ONC's competition here
CHRO vs MRNA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MRNA has a market cap of 31.7B. Regarding current trading prices, CHRO is priced at $1.35, while MRNA trades at $74.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MRNA's P/E ratio is -9.79. In terms of profitability, CHRO's ROE is -1.64%, compared to MRNA's ROE of -0.37%. Regarding short-term risk, CHRO is more volatile compared to MRNA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MRNA's competition here
CHRO vs ROIV Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ROIV has a market cap of 26.1B. Regarding current trading prices, CHRO is priced at $1.35, while ROIV trades at $35.78.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ROIV's P/E ratio is -40.29. In terms of profitability, CHRO's ROE is -1.64%, compared to ROIV's ROE of -0.07%. Regarding short-term risk, CHRO is more volatile compared to ROIV. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ROIV's competition here
CHRO vs INSM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, INSM has a market cap of 24.5B. Regarding current trading prices, CHRO is priced at $1.35, while INSM trades at $113.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas INSM's P/E ratio is -19.62. In terms of profitability, CHRO's ROE is -1.64%, compared to INSM's ROE of -1.30%. Regarding short-term risk, CHRO is more volatile compared to INSM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check INSM's competition here
CHRO vs UTHR Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, UTHR has a market cap of 23.9B. Regarding current trading prices, CHRO is priced at $1.35, while UTHR trades at $558.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas UTHR's P/E ratio is 20.81. In terms of profitability, CHRO's ROE is -1.64%, compared to UTHR's ROE of +0.19%. Regarding short-term risk, CHRO is more volatile compared to UTHR. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check UTHR's competition here
CHRO vs BNTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BNTX has a market cap of 23.8B. Regarding current trading prices, CHRO is priced at $1.35, while BNTX trades at $93.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BNTX's P/E ratio is -20.41. In terms of profitability, CHRO's ROE is -1.64%, compared to BNTX's ROE of -0.07%. Regarding short-term risk, CHRO is more volatile compared to BNTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BNTX's competition here
CHRO vs INCY Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, INCY has a market cap of 23.6B. Regarding current trading prices, CHRO is priced at $1.35, while INCY trades at $117.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas INCY's P/E ratio is 15.87. In terms of profitability, CHRO's ROE is -1.64%, compared to INCY's ROE of +0.29%. Regarding short-term risk, CHRO is more volatile compared to INCY. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check INCY's competition here
CHRO vs BGNE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BGNE has a market cap of 20.2B. Regarding current trading prices, CHRO is priced at $1.35, while BGNE trades at $184.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BGNE's P/E ratio is -22.55. In terms of profitability, CHRO's ROE is -1.64%, compared to BGNE's ROE of +0.12%. Regarding short-term risk, CHRO is more volatile compared to BGNE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BGNE's competition here
CHRO vs DNA-WT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, DNA-WT has a market cap of 18.7B. Regarding current trading prices, CHRO is priced at $1.35, while DNA-WT trades at $0.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas DNA-WT's P/E ratio is N/A. In terms of profitability, CHRO's ROE is -1.64%, compared to DNA-WT's ROE of -0.57%. Regarding short-term risk, CHRO is more volatile compared to DNA-WT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check DNA-WT's competition here
CHRO vs GMAB Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, GMAB has a market cap of 17.9B. Regarding current trading prices, CHRO is priced at $1.35, while GMAB trades at $28.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas GMAB's P/E ratio is 20.99. In terms of profitability, CHRO's ROE is -1.64%, compared to GMAB's ROE of +0.15%. Regarding short-term risk, CHRO is more volatile compared to GMAB. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check GMAB's competition here
CHRO vs NBIX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, NBIX has a market cap of 17.8B. Regarding current trading prices, CHRO is priced at $1.35, while NBIX trades at $177.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas NBIX's P/E ratio is 25.65. In terms of profitability, CHRO's ROE is -1.64%, compared to NBIX's ROE of +0.22%. Regarding short-term risk, CHRO is more volatile compared to NBIX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check NBIX's competition here
CHRO vs ASND Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ASND has a market cap of 16.6B. Regarding current trading prices, CHRO is priced at $1.35, while ASND trades at $269.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ASND's P/E ratio is -110.32. In terms of profitability, CHRO's ROE is -1.64%, compared to ASND's ROE of -56.42%. Regarding short-term risk, CHRO is more volatile compared to ASND. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ASND's competition here
CHRO vs JAZZ Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, JAZZ has a market cap of 15.6B. Regarding current trading prices, CHRO is priced at $1.35, while JAZZ trades at $243.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas JAZZ's P/E ratio is 19.26. In terms of profitability, CHRO's ROE is -1.64%, compared to JAZZ's ROE of +0.01%. Regarding short-term risk, CHRO is more volatile compared to JAZZ. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check JAZZ's competition here
CHRO vs BBIO Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BBIO has a market cap of 15.3B. Regarding current trading prices, CHRO is priced at $1.35, while BBIO trades at $77.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BBIO's P/E ratio is -20.83. In terms of profitability, CHRO's ROE is -1.64%, compared to BBIO's ROE of +0.36%. Regarding short-term risk, CHRO is more volatile compared to BBIO. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BBIO's competition here
CHRO vs EXEL Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, EXEL has a market cap of 14.3B. Regarding current trading prices, CHRO is priced at $1.35, while EXEL trades at $56.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas EXEL's P/E ratio is 17.09. In terms of profitability, CHRO's ROE is -1.64%, compared to EXEL's ROE of +0.40%. Regarding short-term risk, CHRO is more volatile compared to EXEL. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check EXEL's competition here
CHRO vs IONS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, IONS has a market cap of 14.3B. Regarding current trading prices, CHRO is priced at $1.35, while IONS trades at $84.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas IONS's P/E ratio is -50.19. In terms of profitability, CHRO's ROE is -1.64%, compared to IONS's ROE of -0.59%. Regarding short-term risk, CHRO is more volatile compared to IONS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check IONS's competition here
CHRO vs AXSM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, AXSM has a market cap of 12.9B. Regarding current trading prices, CHRO is priced at $1.35, while AXSM trades at $250.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas AXSM's P/E ratio is -65.21. In terms of profitability, CHRO's ROE is -1.64%, compared to AXSM's ROE of -2.60%. Regarding short-term risk, CHRO is more volatile compared to AXSM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check AXSM's competition here
CHRO vs KRTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, KRTX has a market cap of 12.6B. Regarding current trading prices, CHRO is priced at $1.35, while KRTX trades at $329.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas KRTX's P/E ratio is -28.09. In terms of profitability, CHRO's ROE is -1.64%, compared to KRTX's ROE of -0.36%. Regarding short-term risk, CHRO is more volatile compared to KRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check KRTX's competition here
CHRO vs MDGL Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MDGL has a market cap of 12.6B. Regarding current trading prices, CHRO is priced at $1.35, while MDGL trades at $548.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MDGL's P/E ratio is -42.61. In terms of profitability, CHRO's ROE is -1.64%, compared to MDGL's ROE of -0.50%. Regarding short-term risk, CHRO is more volatile compared to MDGL. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MDGL's competition here
CHRO vs SMMT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, SMMT has a market cap of 12.3B. Regarding current trading prices, CHRO is priced at $1.35, while SMMT trades at $15.72.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas SMMT's P/E ratio is -9.93. In terms of profitability, CHRO's ROE is -1.64%, compared to SMMT's ROE of -3.41%. Regarding short-term risk, CHRO is more volatile compared to SMMT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check SMMT's competition here
CHRO vs ARWR Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ARWR has a market cap of 12.3B. Regarding current trading prices, CHRO is priced at $1.35, while ARWR trades at $85.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ARWR's P/E ratio is -40.45. In terms of profitability, CHRO's ROE is -1.64%, compared to ARWR's ROE of -0.55%. Regarding short-term risk, CHRO is more volatile compared to ARWR. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ARWR's competition here
CHRO vs BMRN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BMRN has a market cap of 11.7B. Regarding current trading prices, CHRO is priced at $1.35, while BMRN trades at $60.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BMRN's P/E ratio is 29.01. In terms of profitability, CHRO's ROE is -1.64%, compared to BMRN's ROE of +0.04%. Regarding short-term risk, CHRO is more volatile compared to BMRN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BMRN's competition here
CHRO vs RNAM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RNAM has a market cap of 11.3B. Regarding current trading prices, CHRO is priced at $1.35, while RNAM trades at $72.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RNAM's P/E ratio is -17.39. In terms of profitability, CHRO's ROE is -1.64%, compared to RNAM's ROE of -0.45%. Regarding short-term risk, CHRO is more volatile compared to RNAM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RNAM's competition here
CHRO vs TECH Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TECH has a market cap of 11.1B. Regarding current trading prices, CHRO is priced at $1.35, while TECH trades at $70.53.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TECH's P/E ratio is 36.40. In terms of profitability, CHRO's ROE is -1.64%, compared to TECH's ROE of +0.05%. Regarding short-term risk, CHRO is more volatile compared to TECH. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TECH's competition here
CHRO vs KRYS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, KRYS has a market cap of 10.9B. Regarding current trading prices, CHRO is priced at $1.35, while KRYS trades at $371.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas KRYS's P/E ratio is 49.28. In terms of profitability, CHRO's ROE is -1.64%, compared to KRYS's ROE of +0.19%. Regarding short-term risk, CHRO is more volatile compared to KRYS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check KRYS's competition here
CHRO vs CYTK Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CYTK has a market cap of 10.6B. Regarding current trading prices, CHRO is priced at $1.35, while CYTK trades at $84.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CYTK's P/E ratio is -14.68. In terms of profitability, CHRO's ROE is -1.64%, compared to CYTK's ROE of +1.40%. Regarding short-term risk, CHRO is more volatile compared to CYTK. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CYTK's competition here
CHRO vs CORT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CORT has a market cap of 10.1B. Regarding current trading prices, CHRO is priced at $1.35, while CORT trades at $93.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CORT's P/E ratio is 268.69. In terms of profitability, CHRO's ROE is -1.64%, compared to CORT's ROE of +0.08%. Regarding short-term risk, CHRO is more volatile compared to CORT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CORT's competition here
CHRO vs KYMR Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, KYMR has a market cap of 9.8B. Regarding current trading prices, CHRO is priced at $1.35, while KYMR trades at $117.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas KYMR's P/E ratio is -33.78. In terms of profitability, CHRO's ROE is -1.64%, compared to KYMR's ROE of -0.25%. Regarding short-term risk, CHRO is more volatile compared to KYMR. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check KYMR's competition here
CHRO vs HALO Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, HALO has a market cap of 9.7B. Regarding current trading prices, CHRO is priced at $1.35, while HALO trades at $79.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas HALO's P/E ratio is 17.66. In terms of profitability, CHRO's ROE is -1.64%, compared to HALO's ROE of +1.26%. Regarding short-term risk, CHRO is more volatile compared to HALO. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check HALO's competition here
CHRO vs RXDX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RXDX has a market cap of 9.6B. Regarding current trading prices, CHRO is priced at $1.35, while RXDX trades at $199.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RXDX's P/E ratio is -56.47. In terms of profitability, CHRO's ROE is -1.64%, compared to RXDX's ROE of -0.31%. Regarding short-term risk, CHRO is more volatile compared to RXDX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RXDX's competition here
CHRO vs ABVX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ABVX has a market cap of 9.3B. Regarding current trading prices, CHRO is priced at $1.35, while ABVX trades at $140.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ABVX's P/E ratio is -74.36. In terms of profitability, CHRO's ROE is -1.64%, compared to ABVX's ROE of -1.65%. Regarding short-term risk, CHRO is more volatile compared to ABVX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ABVX's competition here
CHRO vs ALKS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ALKS has a market cap of 9.2B. Regarding current trading prices, CHRO is priced at $1.35, while ALKS trades at $54.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ALKS's P/E ratio is 58.13. In terms of profitability, CHRO's ROE is -1.64%, compared to ALKS's ROE of +0.09%. Regarding short-term risk, CHRO is more volatile compared to ALKS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ALKS's competition here
CHRO vs IBRX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, IBRX has a market cap of 9.2B. Regarding current trading prices, CHRO is priced at $1.35, while IBRX trades at $8.81.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas IBRX's P/E ratio is -27.37. In terms of profitability, CHRO's ROE is -1.64%, compared to IBRX's ROE of +1.39%. Regarding short-term risk, CHRO is more volatile compared to IBRX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check IBRX's competition here
CHRO vs NUVL Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, NUVL has a market cap of 9.1B. Regarding current trading prices, CHRO is priced at $1.35, while NUVL trades at $123.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas NUVL's P/E ratio is -21.75. In terms of profitability, CHRO's ROE is -1.64%, compared to NUVL's ROE of -0.43%. Regarding short-term risk, CHRO is more volatile compared to NUVL. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check NUVL's competition here
CHRO vs PTGX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, PTGX has a market cap of 9B. Regarding current trading prices, CHRO is priced at $1.35, while PTGX trades at $138.26.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas PTGX's P/E ratio is -77.64. In terms of profitability, CHRO's ROE is -1.64%, compared to PTGX's ROE of -0.18%. Regarding short-term risk, CHRO is more volatile compared to PTGX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check PTGX's competition here
CHRO vs TGTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TGTX has a market cap of 8.9B. Regarding current trading prices, CHRO is priced at $1.35, while TGTX trades at $57.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TGTX's P/E ratio is 19.95. In terms of profitability, CHRO's ROE is -1.64%, compared to TGTX's ROE of +0.87%. Regarding short-term risk, CHRO is more volatile compared to TGTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TGTX's competition here
CHRO vs PCVX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, PCVX has a market cap of 8.8B. Regarding current trading prices, CHRO is priced at $1.35, while PCVX trades at $58.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas PCVX's P/E ratio is -8.82. In terms of profitability, CHRO's ROE is -1.64%, compared to PCVX's ROE of -0.33%. Regarding short-term risk, CHRO is more volatile compared to PCVX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check PCVX's competition here
CHRO vs IMGN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, IMGN has a market cap of 8.7B. Regarding current trading prices, CHRO is priced at $1.35, while IMGN trades at $31.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas IMGN's P/E ratio is -111.55. In terms of profitability, CHRO's ROE is -1.64%, compared to IMGN's ROE of -0.93%. Regarding short-term risk, CHRO is more volatile compared to IMGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check IMGN's competition here
CHRO vs BPMC Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BPMC has a market cap of 8.4B. Regarding current trading prices, CHRO is priced at $1.35, while BPMC trades at $129.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BPMC's P/E ratio is -51.58. In terms of profitability, CHRO's ROE is -1.64%, compared to BPMC's ROE of -0.31%. Regarding short-term risk, CHRO is more volatile compared to BPMC. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BPMC's competition here
CHRO vs APGE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, APGE has a market cap of 8.2B. Regarding current trading prices, CHRO is priced at $1.35, while APGE trades at $133.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas APGE's P/E ratio is -30.84. In terms of profitability, CHRO's ROE is -1.64%, compared to APGE's ROE of -0.33%. Regarding short-term risk, CHRO is more volatile compared to APGE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check APGE's competition here
CHRO vs IMVT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, IMVT has a market cap of 8.2B. Regarding current trading prices, CHRO is priced at $1.35, while IMVT trades at $39.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas IMVT's P/E ratio is -15.01. In terms of profitability, CHRO's ROE is -1.64%, compared to IMVT's ROE of -0.68%. Regarding short-term risk, CHRO is more volatile compared to IMVT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check IMVT's competition here
CHRO vs CERE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CERE has a market cap of 8.2B. Regarding current trading prices, CHRO is priced at $1.35, while CERE trades at $44.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CERE's P/E ratio is -16.47. In terms of profitability, CHRO's ROE is -1.64%, compared to CERE's ROE of -0.72%. Regarding short-term risk, CHRO is more volatile compared to CERE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CERE's competition here
CHRO vs RYTM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RYTM has a market cap of 7.9B. Regarding current trading prices, CHRO is priced at $1.35, while RYTM trades at $111.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RYTM's P/E ratio is -36.57. In terms of profitability, CHRO's ROE is -1.64%, compared to RYTM's ROE of -2.03%. Regarding short-term risk, CHRO is more volatile compared to RYTM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RYTM's competition here
CHRO vs MTSR Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MTSR has a market cap of 7.4B. Regarding current trading prices, CHRO is priced at $1.35, while MTSR trades at $70.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MTSR's P/E ratio is -23.58. In terms of profitability, CHRO's ROE is -1.64%, compared to MTSR's ROE of -0.61%. Regarding short-term risk, CHRO is more volatile compared to MTSR. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MTSR's competition here
CHRO vs PTCT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, PTCT has a market cap of 7.4B. Regarding current trading prices, CHRO is priced at $1.35, while PTCT trades at $88.68.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas PTCT's P/E ratio is -38.28. In terms of profitability, CHRO's ROE is -1.64%, compared to PTCT's ROE of +1.00%. Regarding short-term risk, CHRO is more volatile compared to PTCT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check PTCT's competition here
CHRO vs LQDA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, LQDA has a market cap of 7.2B. Regarding current trading prices, CHRO is priced at $1.35, while LQDA trades at $82.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas LQDA's P/E ratio is 580.21. In terms of profitability, CHRO's ROE is -1.64%, compared to LQDA's ROE of +0.47%. Regarding short-term risk, CHRO is more volatile compared to LQDA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check LQDA's competition here
CHRO vs PRAX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, PRAX has a market cap of 6.8B. Regarding current trading prices, CHRO is priced at $1.35, while PRAX trades at $325.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas PRAX's P/E ratio is -24.23. In terms of profitability, CHRO's ROE is -1.64%, compared to PRAX's ROE of -0.43%. Regarding short-term risk, CHRO is more volatile compared to PRAX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check PRAX's competition here
CHRO vs COGT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, COGT has a market cap of 6.8B. Regarding current trading prices, CHRO is priced at $1.35, while COGT trades at $39.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas COGT's P/E ratio is -18.96. In terms of profitability, CHRO's ROE is -1.64%, compared to COGT's ROE of -0.83%. Regarding short-term risk, CHRO is more volatile compared to COGT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check COGT's competition here
CHRO vs MRUS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MRUS has a market cap of 6.8B. Regarding current trading prices, CHRO is priced at $1.35, while MRUS trades at $90.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MRUS's P/E ratio is -17.05. In terms of profitability, CHRO's ROE is -1.64%, compared to MRUS's ROE of -0.51%. Regarding short-term risk, CHRO is more volatile compared to MRUS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MRUS's competition here
CHRO vs SRRK Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, SRRK has a market cap of 6.8B. Regarding current trading prices, CHRO is priced at $1.35, while SRRK trades at $56.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas SRRK's P/E ratio is -15.75. In terms of profitability, CHRO's ROE is -1.64%, compared to SRRK's ROE of -1.64%. Regarding short-term risk, CHRO is more volatile compared to SRRK. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check SRRK's competition here
CHRO vs ACLX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ACLX has a market cap of 6.7B. Regarding current trading prices, CHRO is priced at $1.35, while ACLX trades at $115.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ACLX's P/E ratio is -28.27. In terms of profitability, CHRO's ROE is -1.64%, compared to ACLX's ROE of -0.55%. Regarding short-term risk, CHRO is more volatile compared to ACLX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ACLX's competition here
CHRO vs RETA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, RETA has a market cap of 6.6B. Regarding current trading prices, CHRO is priced at $1.35, while RETA trades at $172.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas RETA's P/E ratio is -66.29. In terms of profitability, CHRO's ROE is -1.64%, compared to RETA's ROE of +0.47%. Regarding short-term risk, CHRO is more volatile compared to RETA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check RETA's competition here
CHRO vs MIRM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MIRM has a market cap of 6.4B. Regarding current trading prices, CHRO is priced at $1.35, while MIRM trades at $126.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MIRM's P/E ratio is -9.43. In terms of profitability, CHRO's ROE is -1.64%, compared to MIRM's ROE of -2.89%. Regarding short-term risk, CHRO is more volatile compared to MIRM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MIRM's competition here
CHRO vs LGND Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, LGND has a market cap of 6.4B. Regarding current trading prices, CHRO is priced at $1.35, while LGND trades at $322.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas LGND's P/E ratio is 38.30. In terms of profitability, CHRO's ROE is -1.64%, compared to LGND's ROE of +0.16%. Regarding short-term risk, CHRO is more volatile compared to LGND. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check LGND's competition here
CHRO vs BLTE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BLTE has a market cap of 6.3B. Regarding current trading prices, CHRO is priced at $1.35, while BLTE trades at $153.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BLTE's P/E ratio is -84.33. In terms of profitability, CHRO's ROE is -1.64%, compared to BLTE's ROE of -0.27%. Regarding short-term risk, CHRO is more volatile compared to BLTE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BLTE's competition here
CHRO vs CNTA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CNTA has a market cap of 6.3B. Regarding current trading prices, CHRO is priced at $1.35, while CNTA trades at $40.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CNTA's P/E ratio is -22.63. In terms of profitability, CHRO's ROE is -1.64%, compared to CNTA's ROE of -0.60%. Regarding short-term risk, CHRO is more volatile compared to CNTA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CNTA's competition here
CHRO vs CGON Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CGON has a market cap of 6.1B. Regarding current trading prices, CHRO is priced at $1.35, while CGON trades at $69.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CGON's P/E ratio is -29.70. In terms of profitability, CHRO's ROE is -1.64%, compared to CGON's ROE of -0.23%. Regarding short-term risk, CHRO is more volatile compared to CGON. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CGON's competition here
CHRO vs CRSP Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CRSP has a market cap of 5.9B. Regarding current trading prices, CHRO is priced at $1.35, while CRSP trades at $59.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CRSP's P/E ratio is -11.89. In terms of profitability, CHRO's ROE is -1.64%, compared to CRSP's ROE of -0.31%. Regarding short-term risk, CHRO is more volatile compared to CRSP. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CRSP's competition here
CHRO vs ERAS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ERAS has a market cap of 5.7B. Regarding current trading prices, CHRO is priced at $1.35, while ERAS trades at $18.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ERAS's P/E ratio is -41.73. In terms of profitability, CHRO's ROE is -1.64%, compared to ERAS's ROE of -0.77%. Regarding short-term risk, CHRO is more volatile compared to ERAS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ERAS's competition here
CHRO vs SYRE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, SYRE has a market cap of 5.7B. Regarding current trading prices, CHRO is priced at $1.35, while SYRE trades at $93.56.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas SYRE's P/E ratio is -45.30. In terms of profitability, CHRO's ROE is -1.64%, compared to SYRE's ROE of -0.31%. Regarding short-term risk, CHRO is more volatile compared to SYRE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check SYRE's competition here
CHRO vs CELC Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CELC has a market cap of 5.6B. Regarding current trading prices, CHRO is priced at $1.35, while CELC trades at $112.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CELC's P/E ratio is -29.67. In terms of profitability, CHRO's ROE is -1.64%, compared to CELC's ROE of -2.45%. Regarding short-term risk, CHRO is more volatile compared to CELC. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CELC's competition here
CHRO vs CDTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CDTX has a market cap of 5.6B. Regarding current trading prices, CHRO is priced at $1.35, while CDTX trades at $221.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CDTX's P/E ratio is -19.77. In terms of profitability, CHRO's ROE is -1.64%, compared to CDTX's ROE of -0.37%. Regarding short-term risk, CHRO is more volatile compared to CDTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CDTX's competition here
CHRO vs ABCM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ABCM has a market cap of 5.5B. Regarding current trading prices, CHRO is priced at $1.35, while ABCM trades at $23.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ABCM's P/E ratio is 2399.00. In terms of profitability, CHRO's ROE is -1.64%, compared to ABCM's ROE of -0.01%. Regarding short-term risk, CHRO is more volatile compared to ABCM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ABCM's competition here
CHRO vs ISEE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ISEE has a market cap of 5.5B. Regarding current trading prices, CHRO is priced at $1.35, while ISEE trades at $39.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ISEE's P/E ratio is -22.44. In terms of profitability, CHRO's ROE is -1.64%, compared to ISEE's ROE of -0.39%. Regarding short-term risk, CHRO is more volatile compared to ISEE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ISEE's competition here
CHRO vs TVTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TVTX has a market cap of 5.4B. Regarding current trading prices, CHRO is priced at $1.35, while TVTX trades at $57.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TVTX's P/E ratio is -262.95. In terms of profitability, CHRO's ROE is -1.64%, compared to TVTX's ROE of -0.27%. Regarding short-term risk, CHRO is more volatile compared to TVTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TVTX's competition here
CHRO vs APLS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, APLS has a market cap of 5.3B. Regarding current trading prices, CHRO is priced at $1.35, while APLS trades at $41.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas APLS's P/E ratio is 38.35. In terms of profitability, CHRO's ROE is -1.64%, compared to APLS's ROE of +0.40%. Regarding short-term risk, CHRO is more volatile compared to APLS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check APLS's competition here
CHRO vs LEGN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, LEGN has a market cap of 5.1B. Regarding current trading prices, CHRO is priced at $1.35, while LEGN trades at $27.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas LEGN's P/E ratio is -40.71. In terms of profitability, CHRO's ROE is -1.64%, compared to LEGN's ROE of -0.25%. Regarding short-term risk, CHRO is more volatile compared to LEGN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check LEGN's competition here
CHRO vs XENE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, XENE has a market cap of 5B. Regarding current trading prices, CHRO is priced at $1.35, while XENE trades at $65.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas XENE's P/E ratio is -13.48. In terms of profitability, CHRO's ROE is -1.64%, compared to XENE's ROE of -0.49%. Regarding short-term risk, CHRO is more volatile compared to XENE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check XENE's competition here
CHRO vs CAI Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CAI has a market cap of 4.9B. Regarding current trading prices, CHRO is priced at $1.35, while CAI trades at $16.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CAI's P/E ratio is -96.09. In terms of profitability, CHRO's ROE is -1.64%, compared to CAI's ROE of +0.06%. Regarding short-term risk, CHRO is more volatile compared to CAI. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CAI's competition here
CHRO vs VKTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, VKTX has a market cap of 4.9B. Regarding current trading prices, CHRO is priced at $1.35, while VKTX trades at $39.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas VKTX's P/E ratio is -10.17. In terms of profitability, CHRO's ROE is -1.64%, compared to VKTX's ROE of -0.71%. Regarding short-term risk, CHRO is more volatile compared to VKTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check VKTX's competition here
CHRO vs MANE Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MANE has a market cap of 4.9B. Regarding current trading prices, CHRO is priced at $1.35, while MANE trades at $118.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MANE's P/E ratio is -37.19. In terms of profitability, CHRO's ROE is -1.64%, compared to MANE's ROE of -0.84%. Regarding short-term risk, CHRO is more volatile compared to MANE. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MANE's competition here
CHRO vs DFTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, DFTX has a market cap of 4.9B. Regarding current trading prices, CHRO is priced at $1.35, while DFTX trades at $45.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas DFTX's P/E ratio is N/A. In terms of profitability, CHRO's ROE is -1.64%, compared to DFTX's ROE of -1.02%. Regarding short-term risk, CHRO is more volatile compared to DFTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check DFTX's competition here
CHRO vs TERN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TERN has a market cap of 4.8B. Regarding current trading prices, CHRO is priced at $1.35, while TERN trades at $52.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TERN's P/E ratio is -51.41. In terms of profitability, CHRO's ROE is -1.64%, compared to TERN's ROE of -0.20%. Regarding short-term risk, CHRO is more volatile compared to TERN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TERN's competition here
CHRO vs EWTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, EWTX has a market cap of 4.6B. Regarding current trading prices, CHRO is priced at $1.35, while EWTX trades at $45.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas EWTX's P/E ratio is -25.98. In terms of profitability, CHRO's ROE is -1.64%, compared to EWTX's ROE of -0.33%. Regarding short-term risk, CHRO is more volatile compared to EWTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check EWTX's competition here
CHRO vs FOLD Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, FOLD has a market cap of 4.5B. Regarding current trading prices, CHRO is priced at $1.35, while FOLD trades at $14.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas FOLD's P/E ratio is -161.00. In terms of profitability, CHRO's ROE is -1.64%, compared to FOLD's ROE of -0.12%. Regarding short-term risk, CHRO is more volatile compared to FOLD. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check FOLD's competition here
CHRO vs AKRO Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, AKRO has a market cap of 4.5B. Regarding current trading prices, CHRO is priced at $1.35, while AKRO trades at $54.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas AKRO's P/E ratio is -14.57. In terms of profitability, CHRO's ROE is -1.64%, compared to AKRO's ROE of -0.22%. Regarding short-term risk, CHRO is more volatile compared to AKRO. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check AKRO's competition here
CHRO vs ACAD Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ACAD has a market cap of 4.5B. Regarding current trading prices, CHRO is priced at $1.35, while ACAD trades at $26.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ACAD's P/E ratio is 12.84. In terms of profitability, CHRO's ROE is -1.64%, compared to ACAD's ROE of +0.36%. Regarding short-term risk, CHRO is more volatile compared to ACAD. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ACAD's competition here
CHRO vs ALPN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, ALPN has a market cap of 4.5B. Regarding current trading prices, CHRO is priced at $1.35, while ALPN trades at $64.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas ALPN's P/E ratio is -101.52. In terms of profitability, CHRO's ROE is -1.64%, compared to ALPN's ROE of -0.13%. Regarding short-term risk, CHRO is more volatile compared to ALPN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check ALPN's competition here
CHRO vs CRNX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CRNX has a market cap of 4.4B. Regarding current trading prices, CHRO is priced at $1.35, while CRNX trades at $83.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CRNX's P/E ratio is -8.19. In terms of profitability, CHRO's ROE is -1.64%, compared to CRNX's ROE of -0.44%. Regarding short-term risk, CHRO is more volatile compared to CRNX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CRNX's competition here
CHRO vs NAMSW Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, NAMSW has a market cap of 4.3B. Regarding current trading prices, CHRO is priced at $1.35, while NAMSW trades at $24.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas NAMSW's P/E ratio is -13.76. In terms of profitability, CHRO's ROE is -1.64%, compared to NAMSW's ROE of -0.30%. Regarding short-term risk, CHRO is more volatile compared to NAMSW. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check NAMSW's competition here
CHRO vs NAMS Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, NAMS has a market cap of 4.3B. Regarding current trading prices, CHRO is priced at $1.35, while NAMS trades at $35.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas NAMS's P/E ratio is -23.26. In terms of profitability, CHRO's ROE is -1.64%, compared to NAMS's ROE of -0.30%. Regarding short-term risk, CHRO is more volatile compared to NAMS. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check NAMS's competition here
CHRO vs OPT Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, OPT has a market cap of 4.2B. Regarding current trading prices, CHRO is priced at $1.35, while OPT trades at $3.41.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas OPT's P/E ratio is -1.52. In terms of profitability, CHRO's ROE is -1.64%, compared to OPT's ROE of +1.18%. Regarding short-term risk, CHRO is more volatile compared to OPT. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check OPT's competition here
CHRO vs DNLI Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, DNLI has a market cap of 4.2B. Regarding current trading prices, CHRO is priced at $1.35, while DNLI trades at $26.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas DNLI's P/E ratio is -9.14. In terms of profitability, CHRO's ROE is -1.64%, compared to DNLI's ROE of -0.52%. Regarding short-term risk, CHRO is more volatile compared to DNLI. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check DNLI's competition here
CHRO vs MRTX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, MRTX has a market cap of 4.1B. Regarding current trading prices, CHRO is priced at $1.35, while MRTX trades at $58.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas MRTX's P/E ratio is -4.82. In terms of profitability, CHRO's ROE is -1.64%, compared to MRTX's ROE of -0.62%. Regarding short-term risk, CHRO is more volatile compared to MRTX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check MRTX's competition here
CHRO vs DNTH Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, DNTH has a market cap of 4B. Regarding current trading prices, CHRO is priced at $1.35, while DNTH trades at $95.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas DNTH's P/E ratio is -23.19. In terms of profitability, CHRO's ROE is -1.64%, compared to DNTH's ROE of -0.02%. Regarding short-term risk, CHRO is more volatile compared to DNTH. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check DNTH's competition here
CHRO vs TLX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TLX has a market cap of 4B. Regarding current trading prices, CHRO is priced at $1.35, while TLX trades at $11.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TLX's P/E ratio is -639.09. In terms of profitability, CHRO's ROE is -1.64%, compared to TLX's ROE of -0.02%. Regarding short-term risk, CHRO is more volatile compared to TLX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TLX's competition here
CHRO vs DYN Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, DYN has a market cap of 3.9B. Regarding current trading prices, CHRO is priced at $1.35, while DYN trades at $23.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas DYN's P/E ratio is -7.40. In terms of profitability, CHRO's ROE is -1.64%, compared to DYN's ROE of -0.58%. Regarding short-term risk, CHRO is more volatile compared to DYN. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check DYN's competition here
CHRO vs BEAM Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, BEAM has a market cap of 3.9B. Regarding current trading prices, CHRO is priced at $1.35, while BEAM trades at $36.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas BEAM's P/E ratio is -12.19. In terms of profitability, CHRO's ROE is -1.64%, compared to BEAM's ROE of -0.06%. Regarding short-term risk, CHRO is more volatile compared to BEAM. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check BEAM's competition here
CHRO vs CPRX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, CPRX has a market cap of 3.9B. Regarding current trading prices, CHRO is priced at $1.35, while CPRX trades at $31.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas CPRX's P/E ratio is 11.33. In terms of profitability, CHRO's ROE is -1.64%, compared to CPRX's ROE of +0.24%. Regarding short-term risk, CHRO is more volatile compared to CPRX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check CPRX's competition here
CHRO vs IDYA Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, IDYA has a market cap of 3.9B. Regarding current trading prices, CHRO is priced at $1.35, while IDYA trades at $38.86.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas IDYA's P/E ratio is -25.32. In terms of profitability, CHRO's ROE is -1.64%, compared to IDYA's ROE of -0.14%. Regarding short-term risk, CHRO is more volatile compared to IDYA. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check IDYA's competition here
CHRO vs TNGX Comparison July 2026
CHRO plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, CHRO stands at 8.9M. In comparison, TNGX has a market cap of 3.8B. Regarding current trading prices, CHRO is priced at $1.35, while TNGX trades at $30.94.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
CHRO currently has a P/E ratio of -0.11, whereas TNGX's P/E ratio is -36.33. In terms of profitability, CHRO's ROE is -1.64%, compared to TNGX's ROE of -0.42%. Regarding short-term risk, CHRO is more volatile compared to TNGX. This indicates potentially higher risk in terms of short-term price fluctuations for CHRO.Check TNGX's competition here